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ABSTRACT
Objectives: Ewing’s sarcoma is an aggressive malignancy of bone and soft tissue in
children and young adults. Despite advances in modern therapy, metastasis can occur
and results in high mortality. The objective of this study was to identify whether the
signaling transduction proteins, insulin growth factor receptor (IGF1R) and S6 kinase
(S6K), can predict poor prognosis in Ewing’s sarcoma.
Methods: After the Institutional Research Board approval, immunohistochemical
experiments on tissue microarray slides containing 32 archived Ewing’s sarcoma
tumor samples were performed with antibodies against IGF1Rβ and p-S6K.
Immunohistochemical staining results were correlated with patients’ clinical data
including clinical stage and overall survival (OS).
Results: Patients had an age range of 12–72 years and 8 (25%) were ≤20 years. After
a follow-up to 14 years, the OS ranged from 25 to 5065 days. High expression of
IGF1Rβ and p-S6K, defined as staining stronger than positive control, was identified in
25% and 68.75% of cases, respectively. Statistical analysis revealed that IGF1Rβ high
expression had a significant association with adverse outcome, shorter OS (P < 0.05),
and near significant association with advanced stage tumors (P = 0.0534). Expression
of S6K exhibited a trend toward shorter survival (P = 0.0934).
Conclusion: High expression or strong staining of IGF1Rβ in Ewing’s sarcoma may
be more important than overall positive staining in identifying poor prognosis and
aggressive cases to be selected for IGF1R inhibitory therapy. More definitive studies
are needed to confirm the role of S6K in the prognosis in Ewing’s sarcoma tumors.

WEBSITE:

ijhs.org.sa

ISSN:

1658-3639

PUBLISHER: Qassim University

Keywords: Ewing’s sarcoma, insulin growth factor 1Rβ, immunohistochemistry, S6
kinase, tissue microarray

Introduction
Ewing’s sarcoma tumor (EST) is the second most common
sarcoma of bone in children and adults that is associated with
metastatic tendency in one-third of cases and subsequent high
mortality.[1,2] Although patients with localized disease can be
cured, metastatic tumors are resistant to conventional therapy
prompting the need to identify additional venues for biologybased treatment.[1,2]
Upregulation and stimulation of insulin growth factor (IGF)
receptors in EST play important roles in tumor growth and
maintenance. The beta subunit of the IGF1 receptor (IGF1Rβ)
spans the cell membrane and is the main subunit responsible for
IGF signal transduction, which subsequently activates mitogenactivated protein and extracellular signal-regulated protein kinases
(MAPK), phosphoinositide 3-kinases, and other proliferative
pathways.[3,4] S6 kinase (S6K) is a family of cytoplasmic ribosomal
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protein kinases that act to promote cell survival and growth.
It activates the 40S ribosomal subunits involved in regulating
translation and inactivates apoptosis through phosphorylation
of the proapoptotic molecule Bcl-2-associated death promoter
BAD.[5] Phosphorylated S6K becomes activated by MAPK and
mammalian target of rapamycin pathways and hence relays
signaling from growth factor receptors to the nucleus [Figure 1].
The consistent expression of IGF1R in pre-clinical experiments
and tumor regression with IGF1R inhibition has led to the
development of several clinical trials IGF1R inhibitors.[6]
Most of these trials have reported variable clinical response
with complete response in <20% of cases.[6] At present, there
are no validated methods to predict such good responders.
In this study, we evaluate the expression of IGF1Rβ in EST,
based on the hypothesis that its high expression in clinical
specimens may serve as indicator of potential clinical response
to targeted therapy.
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Figure 1: Schematic representation of the insulin growth factor pathway and its relationship to intracellular signaling molecules

Materials and Methods
Patients and specimens
After an Institutional Review Board approval, tissue microarray
(TMA) slides were collected from patients with primary and
metastatic EST over a period of 13 years (1995–2007).
Patient consents were waived because of archival nature of
the study. Initial diagnostic biopsies and resection specimens
were collected from the archives of pathology department
at Moffitt Cancer Center, after confirming the diagnosis
by immunohistochemistry (IHC) and molecular methods.
Exclusion criteria include insufficient tumor volume for the
microarray. Patient’s age, sex, clinical stage, and follow-up
data were also compiled as well as follow-up information
up to 14 years after diagnosis. The overall survival (OS) was
calculated (in days) from initial diagnosis until death or last
known follow-up. After confirming the diagnosis of Ewing’s
sarcoma, representative paraffin-embedded tumor cores (0.6
mm in diameter) from initial diagnostic and pre-treatment
specimens were compiled for the construction of TMA blocks
according to a previously described method.[7] Two cores were
obtained from each tumor and placed adjacently in the TMA
blocks.

IHC
Sections for IHC were stained with antibodies for the signaling
proteins, IGF1Rβ (Leica Biosystems, Buffalo Grove, IL)
International Journal of Health Sciences
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and p-S6K (Cell Signaling, Danvers, MA) according to the
manufacturer’s specifications. Automated immunostaining
was performed with a Leica Bond Max instrument (Leica,
Richmond, Illinois). After deparaffinization and antigen
retrieval, tumor microarray and control slides were sequentially
incubated with the primary antibody, a secondary antibody, a
polymer conjugate, and a coloring reagent that gives a brown
color staining. Separate positive controls were made from
breast carcinoma, all of which were previously shown to
exhibit expression of the studied proteins. Negative controls
were stained similarly except for omission of primary
antibodies. Staining of vascular endothelial cells served as
internal positive control.

Analysis of results
IHC staining results were recorded by two pathologists.
Identifiable staining was classified as low (weak or less than
that of internal positive control) or high (equal or stronger
than internal positive control). Because of the limited
specimen sizes, data on the extent of the staining (focal
versus diffuse) were not collected. For statistical purposes,
negative and low staining results were grouped together
and compared to high staining (high expression). Kaplan–
Meier survival curves were also plotted to demonstrate any
difference in survival between the staining groups of the
selected proteins. The association of other clinicopathologic
parameters and IHC expression was also examined by Fisher
exact Chi-square test using an online software http://www.
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socscistatistics.com/tests/chisquare. P < 0.05 was considered
statistically significant.

insignificant, association with advanced tumors (regional
extension + metastatic) (P = 0.0534).

Results

Staining for p-S6K revealed distinct cytoplasmic labeling
[Figure 2]. High p-S6K expression was noted in 22/32
(68.75%) cases and did not demonstrate any significant
association with age, gender, or clinical stage. There was a
trend but no statistically significant difference in OS between
tumors with negative/low versus high expression on Kaplan–
Meier curves (P = 0.0934). There was no correlation between
the expressions of IGF1Rβ and S6K [Table 1].

Patients and tumors
Clinical and survival data were collected from an initial cohort
of 36 patients whose clinical information was previously
published.[8] Subsequent review of the stained sections revealed
loss of stainable tissue in four cases. Of the remaining 32
patients, 21 were male and 11 females (M:F=1.9) and had an
age range of 12–72 years. Twenty-four (75%) patients were
older than 20 years and 8 (25%) were pediatric (≤20 years).
Patients had follow-up visits extending from 25 days to 14
years from the primary diagnosis. The OS ranged from 25 to
5065 days.
Tumor samples were from primary locations in 26 patients and
from metastatic sites in six patients. Of the primary locations,
18 (56.25%) patients had skeletal tumors and 8 (25%) tumors
were extraskeletal. Tumor sizes ranged from 1.2 to 34.5 cm
(measured in 22 patients). Clinical stage was determined in
28 cases and was grouped into localized (12 cases), regional
extension (8 cases), and distant metastasis (8 cases), Table 1.

IHC results and statistical analysis
IGF1Rβ IHC staining was membranous with no discernible
cytoplasmic or nuclear labeling [Figure 2]. Immunostaining
was variable and ranged from negative, low, to high staining.
High IGF1Rβ expression was seen in 8/32 cases (25%). High
staining did not correlate with a specific age group, gender, or
tumor location [Table 1]. All the patients with high expression
were dead at the end of follow-up. High expression was
significantly associated with bad outcome (P = 0.0048). High
IGF1Rβ staining also revealed a significant association with
shorter OS [P = 0.0398, Figure 2]. Of these eight tumors, one
was localized, three were metastatic, and four with regional
extension. High staining also showed a trend, albeit statistically

Discussion
This study documents and confirms the importance of
IGF1Rβ and S6K in EST growth and the results are
congruent with few previous studies from in vitro cell lines
and immunohistochemical studies that have revealed wide
expression of IGF1R in EST and its downregulation after
treatment with inhibitors.[9-11] Our results, highlighting the worse
prognosis associated with IGF1R expression, are in agreement
with these findings which were the basis for using IGF1R
inhibitors in several preclinical and clinical EST trials.[9-11]
However, other studies were contradictory and reported higher
IGF1R mRNA and nuclear protein expression in association
with better prognosis.[12,13] The reason behind this discrepancy
is not clear and may be related to methodical differences or to
the presence of uncharted complexities in IGF1R pathway. Our
study emphasizes only strong cytoplasmic staining of IFG1R
expression as the predictor of bad prognosis.
In many clinical trials, EST treatment with various IGF1R
inhibitors has resulted in resistance with less satisfactory
results.[6,14] Although more than 1 mechanism can explain this
resistance as outlined earlier, cross-signaling and cross-talk
with other signaling molecules may result in the activation
of other downstream pathways, bypassing IGF1R inhibition
and leading to the maintenance of tumor growth. Combined
inhibitors of other signaling networks in a synergistic manner

Table 1: IGF1R expression in relation to clinicopathological data stratification, n=32
Clinicopathologic parameters

Data stratification

Number (%) with high expression

Total number of cases (%)

P-value

Age (years)

≤20

3 (9.4)

8 (25)

0.2479

>20

5 (15.6)

24 (75)

Males

5 (15.6)

21 (65.6)

Females

3 (9.4)

11 (34.4)

Alive

0 (6.7)

15 (46.9)

Dead

8 (18.8)

17 (53.1)

Localized

1 (6.7)

12 (37.5)

Advanced*

7 (18.8)

16 (50.0)

0 (0)

4 (12.5)

High

6 (18.8)

22 (68.75)

Negative/low

2 (6.7)

10

Gender
Patients’ outcome
Clinical stage

Unknown
S6K expression

0.7078
0.0048
0.0534

0.2565

*Distance metastasis and regional extension groups were added together as “advanced category” and statistically compared to the localized group
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Figure 2: High staining with IGF1Rβ revealing strong diffuse membranous staining (a. ×200). Faint positive staining that is weaker than
endothelial staining is considered low (b. ×200). High staining with p-S6K (c. ×200) manifested as diffuse cytoplasmic labeling. (d) Kaplan–
Meier survival curve revealed a significant difference in the overall survival between tumors expressing high (solid line) versus low/negative
expressors (interrupted line --------), logrank P = 0.0398

have proven to be a more logical approach to overcome
chemoresistance.[15,16]
In this regard, we examined the expression of p-S6K in
EST and highlighted a trend association with worse survival
indicating a potential marker of poor prognosis in EST.
Activation of S6K is part of the intracellular signaling cascade
of IGF1R and plays a role in MAPK signal transduction. A
previous study has revealed that S6K phosphorylation is linked
to AKT apoptosis pathway and is decreased significantly with
silencing or inhibition of the AKT substrate, PRAS40, which
is another target of insulin action.[17] S6K has been found to
play a role in resistance to IGF1R inhibitor therapy in other
tumors.[18] In neuroblastoma cell lines, the activation of S6K
was associated with decreased responsiveness to IGF1R
inhibition.[19] On the other hand, inhibition of S6K increases
the sensitivity of colon carcinoma cells to IGF1R inhibitor.[20]
S6K is a central signaling molecule and its expression in EST
makes it an attractive target for inhibitory therapy. Synergistic
IGF1R/S6K inhibitors may help overcome EST resistance to
IGF1R targeted therapy.

stresses the importance of only high IGF1Rβ staining as
indicator of aggressive EST and potential clinical response
to IGF1R inhibitory therapy. Further studies on p-S6K in
EST, particularly with larger number of cases and statistical
association studies, are necessary for better understanding of
its role in EST targeted therapy.
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